![Wendy Chang](https://cdn.zonebourse.com/static/resize/768/576//static/images/insiders/unknown.png)
Wendy Chang
Ufficiale delle Risorse Umane presso HARPOON THERAPEUTICS, INC.
Profilo
Wendy Chang is currently the Chief People Officer at Harpoon Therapeutics, Inc. She previously worked at IDbyDNA, Inc. as the Head of People & Culture.
Ms. Chang completed her undergraduate degree at the University of California.
Posizioni attive di Wendy Chang
Società | Posizione | Inizio |
---|---|---|
HARPOON THERAPEUTICS, INC. | Ufficiale delle Risorse Umane | 06/07/2022 |
Precedenti posizioni note di Wendy Chang
Società | Posizione | Fine |
---|---|---|
IDbyDNA, Inc.
![]() IDbyDNA, Inc. BiotechnologyHealth Technology IDbyDNA, Inc. operates as a precision medicine company that focuses on metagenomic approaches for infectious disease identification. It develops technologies to enable universal microorganism detection. The firm help doctors and scientists to detect any pathogen in any sample, thereby removing barriers for the adoption of metagenomics in clinical settings, ultimately leading to faster public health responses during infectious disease outbreaks. The company was founded by Martin G. Reese, Guochun Liao, Mark Yandell, and Robert Schlaberg in Noveber 2014 and is headquartered in San Mateo, CA. | Ufficiale delle Risorse Umane | - |
Formazione di Wendy Chang
University of California | Undergraduate Degree |
Esperienze
Posizioni ricoperte
Attive
Inattive
Società quotate in Borsa
Aziende private
Relazioni
Relazioni di 1° grado
Aziende connesse in 1º grado
Uomo
Donna
Amministratori
Dirigenti
Società collegate
Aziende private | 2 |
---|---|
Harpoon Therapeutics, Inc.
![]() Harpoon Therapeutics, Inc. BiotechnologyHealth Technology Harpoon Therapeutics, Inc. is a clinical-stage immunotherapy company, which engages in the development of antibodies. It focuses on the research of novel class of T cell engagers that harness the power of the body’s immune system to treat patients suffering from cancer and other diseases. The firm utilizes its proprietary Tri-specific T cell Activating Construct platform to create a pipeline of novel TriTACs for the treatment of solid tumors and hematologic malignancies. The company was founded by Patrick A. Baeuerle, Luke B. Evnin, and Jeanmarie Guenot on March 19, 2015 and is headquartered in South San Francisco, CA. | Health Technology |
IDbyDNA, Inc.
![]() IDbyDNA, Inc. BiotechnologyHealth Technology IDbyDNA, Inc. operates as a precision medicine company that focuses on metagenomic approaches for infectious disease identification. It develops technologies to enable universal microorganism detection. The firm help doctors and scientists to detect any pathogen in any sample, thereby removing barriers for the adoption of metagenomics in clinical settings, ultimately leading to faster public health responses during infectious disease outbreaks. The company was founded by Martin G. Reese, Guochun Liao, Mark Yandell, and Robert Schlaberg in Noveber 2014 and is headquartered in San Mateo, CA. | Health Technology |
- Borsa valori
- Insiders
- Wendy Chang